Literature DB >> 18979640

Serum prohepcidin reflects the degree of liver function impairment in liver cirrhosis.

Jerzy Jaroszewicz1, Magdalena Rogalska, Robert Flisiak.   

Abstract

In the past few years the role of hepcidin metabolism disturbances, a recently described key regulator of iron metabolism, has been raised in patients with chronic liver diseases. The aim of this study was to assess the serum concentrations of prohepcidin in liver cirrhosis of various aetiologies and their possible relationship with the disease activity. Prohepcidin was measured in the sera of 70 patients with liver cirrhosis of various aetiologies by an immunoassay technique. The serum concentrations of prohepcidin were compared with the degree of liver insufficiency and biochemical markers of iron metabolism. A significant decrease in serum prohepcidin was observed in patients with liver cirrhosis compared with healthy individuals (52.6 +/- 1.9 vs 79.5 +/- 9.7 ng ml(-1), p<0.01); this was most prominent in patients with hepatitis C virus and alcohol-related liver cirrhosis. The association between serum prohepcidin and the degree of liver dysfunction was observed in alcoholic liver cirrhosis, as illustrated through the inverse correlation with the Child-Pugh score (r = -0.41, p<0.01). In conclusion, serum prohepcidin concentration is lowered in liver cirrhosis, which at least to some extent, may be a result of impaired liver function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18979640     DOI: 10.1080/13547500802033391

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  8 in total

1.  Decreased prohepcidin levels in patients with HBV-related liver disease: relation with ferritin levels.

Authors:  Oya Yonal; Filiz Akyuz; Kadir Demir; Sevgi Ciftci; Fahriye Keskin; Binnur Pinarbasi; Ahmet Uyanikoglu; Halim Issever; Sadakat Ozdil; Gungor Boztas; Fatih Besisik; Sabahattin Kaymakoglu; Yilmaz Cakaloglu; Zeynel Mungan; Atilla Okten
Journal:  Dig Dis Sci       Date:  2010-03-18       Impact factor: 3.199

2.  Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic hepatitis C.

Authors:  Jerzy Jaroszewicz; Magdalena Rogalska; Iwona Flisiak; Robert Flisiak
Journal:  World J Gastroenterol       Date:  2010-04-14       Impact factor: 5.742

Review 3.  Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker.

Authors:  Driton Vela
Journal:  Mol Med       Date:  2018-03-15       Impact factor: 6.354

4.  The relationship between anemia, liver disease, and hepcidin levels in hemodialysis patients with hepatitis.

Authors:  A Zumrutdal; N Sezgin
Journal:  Indian J Nephrol       Date:  2012-11

5.  Inhibiting heme oxygenase-1 attenuates rat liver fibrosis by removing iron accumulation.

Authors:  Qiu-Ming Wang; Jian-Ling Du; Zhi-Jun Duan; Shi-Bin Guo; Xiao-Yu Sun; Zhen Liu
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.374

Review 6.  The pathophysiology of thrombocytopenia in chronic liver disease.

Authors:  Oscar Mitchell; David M Feldman; Marla Diakow; Samuel H Sigal
Journal:  Hepat Med       Date:  2016-04-15

7.  Hepcidin levels in children with chronic liver disease.

Authors:  Murat Cakir; Erol Erduran; Elif Sag Turkmen; Yuksel Aliyazicioglu; Gokce Pinar Reis; Umit Cobanoglu; Selim Demir
Journal:  Saudi J Gastroenterol       Date:  2015 Sep-Oct       Impact factor: 2.485

8.  Correlation of serum hepcidin levels with disease progression in hepatitis B virus-related disease assessed by nanopore film based assay.

Authors:  Jing Wang; Ailian Dong; Gang Liu; Gregory J Anderson; Tony Y Hu; Jian Shi; Yulin Hu; Guangjun Nie
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.